Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Camprubi, Daniel; Almuedo-Riera, Alex; Marti-Soler, Helena; Soriano, Alex; Hurtado, Juan Carlos; Subira, Carme; Grau-Pujol, Berta; Krolewiecki, Alejandro; Munoz, Jose
PLOS ONE
2020
VL / 15 - BP / - EP /
abstract
Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
MENTIONS DATA
Among papers in Immunology
143rd
Influratio
152
PROYECTO FINANCIADO POR PLAN NACIONAL DE INVESTIGACIÓN AGENCIA ESTATAL DE INVESTIGACIÓN, MINISTERIO DE CIENCIA E INNOVACIÓN. PID2019-109127RB-I00
- BETA VERSION
Más información
Influscience
Rankings
- BETA VERSION
